Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366919 | 1.00 | IDO1 (0.42) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL31689794 | 0.83 | TAAR1 (0.50) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL31689793 | 0.83 | TAAR1 (0.50) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL6172860 | 0.81 | ALOX5 (0.46) | IDO1TAAR1CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL12948348 | 0.81 | L3MBTL1 (0.47) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL10889311 | 0.81 | MEN1 (0.51) | ALDH1A1MAPTKDM4ELMNAPOLB | |
| SCHEMBL17804 | 0.80 | IDO1 (0.57) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL29377714 | 0.80 | IDO1 (0.57) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL13744996 | 0.80 | GABRA1 (0.48) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL2811529 | 0.79 | GABRA1 (0.42) | TAAR1ALDH1A1MAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4624447-A1 | METHODS OF MAKING AND USING 1-METHYLEFFUSOL | Laboratory for Synthetic Chemistry and Chemical Biology Limited (HK) | 2025-10-01 | — | — | EP | claimed |
| EP-4624447-A1 | METHODS OF MAKING AND USING 1-METHYLEFFUSOL | Laboratory for Synthetic Chemistry and Chemical Biology Limited (HK) | 2025-10-01 | — | — | EP | disclosed |
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | EIL TERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2010127307-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2A1 | IDO1 308/4885TAAR1 3314/4885CA12 3074/4885 |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | BCL2, BCL2L1, BCL2A1 | IDO1 308/4885TAAR1 3314/4885CA12 3074/4885 |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | IDO1 4227/4885TAAR1 4290/4885CA12 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.